FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / PeerJ / Tiludronate concentrations and cytologic findings in synovia...
PeerJ2015; 3; e889; doi: 10.7717/peerj.889

Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses.

Abstract: Anecdotal accounts of tiludronate administration via intravenous regional limb perfusion (IVRLP) exist despite a lack of information regarding safety for synovial structures in the perfused area. The objective of this study was to determine whether tiludronate concentrations in synovial structures after IVRLP with low dose (0.5 mg, LDT) or high dose (50 mg, HDT) tiludronate remain below a value demonstrated in vitro to be safe for articular cartilage (<19,000 ng/ml), and to determine effects of tiludronate on synovial fluid cytology variables compared to saline perfused control limbs. Using a randomized controlled experimental study design, horses received IVRLP with LDT (n = 6) or HDT (n = 6) in one forelimb and IVRLP with saline in the contralateral limb. Synovial fluid cytology variables and tiludronate concentrations were evaluated in navicular bursae (NB), and distal interphalangeal (DIP) and metacarpophalangeal (MCP) joints one week before and 30-45 min after IVRLP, and in DIP and MCP joints 24 h after IVRLP. Data were analyzed with 2-way rmANOVA (p 19,000 ng/ml in DIP joints of two HDT limbs. Tiludronate was measurable only in synovial fluid from HDT limbs 24 h post-perfusion. There were no differences in synovial fluid cytology variables between control and treated limbs. Conclusions. In some horses, IVRLP with HDT may result in synovial fluid concentrations of tiludronate that may have adverse effects on articular cartilage, based on in vitro data. IVRLP with LDT is unlikely to promote articular cartilage degradation. Further studies to determine a safe and effective dose for IVRLP with tiludronate are needed.
Get Full Text
Publication Date: 2015-04-28 PubMed ID: 25945303PubMed Central: PMC4419440DOI: 10.7717/peerj.889Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research explores the safety of tiludronate, administered to horses through intravenous regional limb perfusion (IVRLP). The aim was to assess whether tiludronate concentrations remained below a safe threshold for articular cartilage, and to examine its effects on synovial fluid cytology variables.

Objective and Methodology

  • The objective this study was to measure the concentration of tiludronate, a drug commonly used in horses, in the synovial structures following IVRLP.
  • The study aimed to establish whether the concentration levels remained within an in vitro safe threshold for articular cartilage, that is under 19,000 nanograms per milliliter (ng/ml).
  • Furthermore, the study aimed to assess the effects of tiludronate on synovial fluid cytology variables, comparing it to saline-perfused control limbs.
  • To achieve these goals, the researchers employed a controlled experimental design, administering tiludronate to horses at both low (0.5 milligram, LDT) and high (50 milligram, HDT) doses.

Results and Findings

  • After administration, the synovial fluid cytology variables and tiludronate concentrations were evaluated in three different areas: the navicular bursae (NB), the distal interphalangeal (DIP) and the metacarpophalangeal (MCP) joints of horses. This occurred one week before, and 30-45 minutes and 24 hours after IVRLP.
  • The peak concentration of tiludronate in the synovial fluid was found 30-45 minutes after perfusion.
  • Mean tiludronate concentrations significantly differed based on the administered dosage, with lesser concentrations in LDT limbs compared to the HDT ones.
  • In the DIP joints of two horses who received the high dose treatment, the tiludronate concentration exceeded the safe limit of 19,000 ng/ml.
  • After 24 hours, tiludronate was only detectable in the synovial fluid of HDT limbs.
  • No notable differences were observed in synovial fluid cytology variables between the control and treated limbs.

Conclusions and Further Research

  • The study concluded that IVRLP with a high dose of tiludronate may result in concentrations which could potentially harm the articular cartilage of horses.
  • However, administration with a low dose of tiludronate is unlikely to cause cartilage degradation.
  • As such, further studies are needed to establish a safe and effective dose for IVRLP administration of tiludronate.

Cite This Article

APA
Hunter BG, Duesterdieck-Zellmer KF, Larson MK. (2015). Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses. PeerJ, 3, e889. https://doi.org/10.7717/peerj.889

Publication

PeerJ
ISSN: 2167-8359
NlmUniqueID: 101603425
Country: United States
Language: English
Volume: 3
Pages: e889
PII: e889

Researcher Affiliations

Hunter, Barbara G
  • Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University , Corvallis, OR , USA.
Duesterdieck-Zellmer, Katja F
  • Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University , Corvallis, OR , USA.
Larson, Maureen K
  • Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University , Corvallis, OR , USA.

Conflict of Interest Statement

The authors declare there are no competing interests.

References

This article includes 29 references
  1. Bonjour JP, Ammann P, Barbier A, Caverzasio J, Rizzoli R. Tiludronate: bone pharmacology and safety.. Bone 1995 Nov;17(5 Suppl):473S-477S.
    doi: 10.1016/8756-3282(95)00344-9pubmed: 8573421google scholar: lookup
  2. Boyce M, Malone ED, Anderson LB, Park S, Godden SM, Jenner F, Trumble TN. Evaluation of diffusion of triamcinolone acetonide from the distal interphalangeal joint into the navicular bursa in horses.. Am J Vet Res 2010 Feb;71(2):169-75.
    doi: 10.2460/ajvr.71.2.169pubmed: 20113224google scholar: lookup
  3. Butt TD, Bailey JV, Dowling PM, Fretz PB. Comparison of 2 techniques for regional antibiotic delivery to the equine forelimb: intraosseous perfusion vs. intravenous perfusion.. Can Vet J 2001 Aug;42(8):617-22.
    pmc: PMC1476572pubmed: 11519271
  4. Carpenter RS. How to treat dorsal metacarpal disease with regional tiludronate and extracorporeal shock wave therapies in Thoroughbred racehorses. Proceedings of the annual convention of the american association of equine practitioners Anaheim. 2012. pp. 546–549.
  5. Coudry V, Thibaud D, Riccio B, Audigié F, Didierlaurent D, Denoix JM. Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column.. Am J Vet Res 2007 Mar;68(3):329-37.
    doi: 10.2460/ajvr.68.3.329pubmed: 17331024google scholar: lookup
  6. Davidson EJ, Orsini JA. Arthrocentesis and synovial fluid analysis. Equine emergencies: treatment and procedures 3rd edition. St. Louis: Saunders Elsevier; 2007. pp. 272–273.
  7. Delguste C, Amory H, Guyonnet J, Thibaud D, Garnero P, Detilleux J, Lepage OM, Doucet M. Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1.. J Vet Pharmacol Ther 2008 Apr;31(2):108-16.
    doi: 10.1111/j.1365-2885.2007.00936.xpubmed: 18307502google scholar: lookup
  8. Denoix JM, Thibaud D, Riccio B. Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial.. Equine Vet J 2003 Jun;35(4):407-13.
    doi: 10.2746/042516403776014226pubmed: 12880010google scholar: lookup
  9. Duesterdieck-Zellmer KF, Driscoll N, Ott JF. Concentration-dependent effects of tiludronate on equine articular cartilage explants incubated with and without interleukin-1β.. Am J Vet Res 2012 Oct;73(10):1530-9.
    doi: 10.2460/ajvr.73.10.1530pubmed: 23013178google scholar: lookup
  10. Duesterdieck-Zellmer KF, Moneta L, Ott JF, Larson MK, Gorman EM, Hunter B, Löhr CV, Payton ME, Morré JT, Maier CS. Effects of low and high dose intraarticular tiludronate on synovial fluid and clinical variables in healthy horses-a preliminary investigation.. PeerJ 2014;2:e534.
    doi: 10.7717/peerj.534pmc: PMC4157236pubmed: 25237596google scholar: lookup
  11. Dulin JA, Drost WT, Phelps MA, Santschi EM, Menendez MI, Bertone AL. Influence of exercise on the distribution of technetium Tc 99m medronate following intra-articular injection in horses.. Am J Vet Res 2012 Mar;73(3):418-25.
    doi: 10.2460/ajvr.73.3.418pubmed: 22369536google scholar: lookup
  12. Gough MR, Thibaud D, Smith RK. Tiludronate infusion in the treatment of bone spavin: a double blind placebo-controlled trial.. Equine Vet J 2010 Jul;42(5):381-7.
    doi: 10.1111/j.2042-3306.2010.00120.xpubmed: 20636772google scholar: lookup
  13. Hyde RM, Lynch TM, Clark CK, Slone DE, Hughes FE. The influence of perfusate volume on antimicrobial concentration in synovial fluid following intravenous regional limb perfusion in the standing horse.. Can Vet J 2013 Apr;54(4):363-7.
    pmc: PMC3595939pubmed: 24082163
  14. Kamm L, Mcllwraith W, Kawcak C. A review of the efficacy of tiludronate in the horse. Journal of Equine Veterinary Science 2008;28:209–214.
    doi: 10.1016/j.jevs.2008.02.007google scholar: lookup
  15. Kelmer G, Bell GC, Martin-Jimenez T, Saxton AM, Catasus C, Elliot SB, Meibohm B. Evaluation of regional limb perfusion with amikacin using the saphenous, cephalic, and palmar digital veins in standing horses.. J Vet Pharmacol Ther 2013 Jun;36(3):236-40.
    doi: 10.1111/j.1365-2885.2012.01414.xpubmed: 22607056google scholar: lookup
  16. Kelmer G, Martin-Jimenez T, Saxton AM, Catasus C, Elliot SB, Lakritz J. Evaluation of regional limb perfusion with erythromycin using the saphenous, cephalic, or palmar digital veins in standing horses.. J Vet Pharmacol Ther 2013 Oct;36(5):434-40.
    doi: 10.1111/jvp.12028pubmed: 23240633google scholar: lookup
  17. Levine DG, Epstein KL, Ahern BJ, Richardson DW. Efficacy of three tourniquet types for intravenous antimicrobial regional limb perfusion in standing horses.. Vet Surg 2010 Dec;39(8):1021-4.
    doi: 10.1111/j.1532-950X.2010.00732.xpubmed: 20880139google scholar: lookup
  18. Mahaffey EA. Synovial fluid. Diagnostic cytology and hematology of the horse 2nd edition. St. Louis: Mosby; 2002. pp. 163–170.
  19. Mahne AT, Rioja E, Marais HJ, Villarino NF, Rubio-Martinez LM. Clinical and pharmacokinetic effects of regional or general anaesthesia on intravenous regional limb perfusion with amikacin in horses.. Equine Vet J 2014 May;46(3):375-9.
    doi: 10.1111/evj.12125pubmed: 23789781google scholar: lookup
  20. Murphey ED, Santschi EM, Papich MG. Regional intravenous perfusion of the distal limb of horses with amikacin sulfate.. J Vet Pharmacol Ther 1999 Feb;22(1):68-71.
    doi: 10.1046/j.1365-2885.1999.00180.xpubmed: 10211721google scholar: lookup
  21. Parra-Sanchez A, Lugo J, Boothe DM, Gaughan EM, Hanson RR, Duran S, Belknap JK. Pharmacokinetics and pharmacodynamics of enrofloxacin and a low dose of amikacin administered via regional intravenous limb perfusion in standing horses.. Am J Vet Res 2006 Oct;67(10):1687-95.
    doi: 10.2460/ajvr.67.10.1687pubmed: 17014317google scholar: lookup
  22. Patntirapong S, Singhatanadgit W, Chanruangvanit C, Lavanrattanakul K, Satravaha Y. Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition.. J Oral Pathol Med 2012 Oct;41(9):713-20.
    doi: 10.1111/j.1600-0714.2012.01154.xpubmed: 22563819google scholar: lookup
  23. Rubio-Martínez LM, Cruz AM. Antimicrobial regional limb perfusion in horses.. J Am Vet Med Assoc 2006 Mar 1;228(5):706-12, 655.
    doi: 10.2460/javma.228.5.706pubmed: 16506931google scholar: lookup
  24. Rubio-Martínez LM, López-Sanromán J, Cruz AM, Tendillo F, Rioja E, San Román F. Evaluation of safety and pharmacokinetics of vancomycin after intraosseous regional limb perfusion and comparison of results with those obtained after intravenous regional limb perfusion in horses.. Am J Vet Res 2006 Oct;67(10):1701-7.
    doi: 10.2460/ajvr.67.10.1701pubmed: 17014319google scholar: lookup
  25. Sanchez Teran AF, Rubio-Martinez LM, Villarino NF, Sanz MG. Effects of repeated intra-articular administration of amikacin on serum amyloid A, total protein and nucleated cell count in synovial fluid from healthy horses.. Equine Vet J Suppl 2012 Dec;(43):12-6.
    doi: 10.1111/j.2042-3306.2012.00637.xpubmed: 23447871google scholar: lookup
  26. Stashak TS. Examination for lameness. Adams lameness in horses 5th edition. Philadelphia: Lippincott Williams & Wilkins; 2002. pp. 113–175.
  27. Varela AM, Lepage OM, Doucet M, Marcoux M, Garnero P. Tiludronate chez le cheval: tolerance et effets a court terme sur le metabolisme osseux. Annales de Médecine Vétérinaire 2002;147:123–130.
  28. Wagner AE, McIlwraith CW, Martin GS. Effect of intra-articular injection of orgotein and saline solution on equine synovia.. Am J Vet Res 1982 Apr;43(4):594-7.
    pubmed: 7073079
  29. White KK, Hodgson DR, Hancock D, Parry BW, Cordell C. Changes in equine carpal joint synovial fluid in response to the injection of two local anesthetic agents.. Cornell Vet 1989 Jan;79(1):25-38.
    pubmed: 2912672

Citations

This article has been cited 1 times.
  1. Mizobe F, Nomura M, Kato T, Nambo Y, Yamada K. Signal changes in standing magnetic resonance imaging of osseous injury at the origin of the suspensory ligament in four Thoroughbred racehorses under tiludronic acid treatment. J Equine Sci 2017;28(3):87-97.
    doi: 10.1294/jes.28.87pubmed: 28955160google scholar: lookup
Subscribe to our newsletter
Join 99,006 horse owners like you who receive our email updates on horse health and nutrition.